Anne Li April 23rd, 2017
An immunotherapy drug is too expensive to be given to NHS patients with head and neck cancers in England, according to the NHS drugs watchdog. In draft guidance, the National Institute for Health and Care Excellence (NICE) said it could not recommend nivolumab (Opdivo) for the treatment of advanced head and neck cancer. “Since this is not NICE’s final decision on nivolumab we would urge the drug company and NHS England to get round the table, working in partnership, to make this drug available for patients in England,” said Sara Bainbridge, Cancer Research UK’s policy manager.
See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-04-12-immunotherapy-drug-too-costly-for-head-and-neck-cancer